Literature DB >> 24051063

Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers.

Kelly E Dunn1, Kathryn A Saulsgiver, Mollie E Patrick, Sarah H Heil, Stephen T Higgins, Stacey C Sigmon.   

Abstract

BACKGROUND: The high rates of HIV and Hepatitis C (HCV) infection among opioid abusers is a serious public health problem, and efforts to enhance knowledge regarding risks for HIV/hepatitis infection in this population are important. Abuse of prescription opioids (POs), in particular, has increased substantially in the past decade and is associated with increasing rates of injection drug use and HCV infection.
METHODS: This study describes the effects of a brief HIV/HCV educational intervention delivered in the context of a larger randomized, double-blind clinical trial evaluating the relative efficacy of 1-, 2-, and 4-week outpatient buprenorphine tapers and subsequent oral naltrexone maintenance for treating PO dependence. HIV- and HCV-related knowledge and risk behaviors were characterized pre- and post-intervention in 54 primary PO abusers.
RESULTS: The educational intervention was associated with significant improvements in HIV (p<.001) and HCV (p<.001) knowledge. Significant improvements (p<.001) were observed on all three domains of the HIV questionnaire (i.e., general knowledge, sexual risk behaviors, drug risk behaviors) and on 21 and 11 individual items on the HIV and HCV questionnaires, respectively. Self-reported likelihood of using a condom also increased significantly (p<.05) from pre- to post-intervention. No additional changes in self-reported risk behaviors were observed.
CONCLUSION: These results suggest that a brief, easy-to-administer intervention is associated with substantial gains in HIV and HCV knowledge among PO abusers and represents the necessary first step toward the dissemination of a structured prevention HIV and HCV intervention for PO abusers.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Education; HIV; Hepatitis C; Intervention; Noninjection; Prescription opioids

Mesh:

Substances:

Year:  2013        PMID: 24051063      PMCID: PMC3824383          DOI: 10.1016/j.drugalcdep.2013.08.007

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  51 in total

Review 1.  HIV prevention for injecting drug users: the first 25 years and counting.

Authors:  Don C Des Jarlais; Salaam Semaan
Journal:  Psychosom Med       Date:  2008-06-02       Impact factor: 4.312

2.  Unprotected sexual behavior among heterosexual HIV-positive injection drug using men: associations by partner type and partner serostatus.

Authors:  David W Purcell; Yuko Mizuno; Lisa R Metsch; Richard Garfein; Karin Tobin; Kelly Knight; Mary H Latka
Journal:  J Urban Health       Date:  2006-07       Impact factor: 3.671

3.  Behavioral HIV risk reduction among people who inject drugs: meta-analytic evidence of efficacy.

Authors:  Michael M Copenhaver; Blair T Johnson; I-Ching Lee; Jennifer J Harman; Michael P Carey
Journal:  J Subst Abuse Treat       Date:  2006-07-13

4.  Characterizing and improving HIV/AIDS knowledge among cocaine-dependent outpatients.

Authors:  Sarah H Heil; Stacey C Sigmon; Joan A Mongeon; Stephen T Higgins
Journal:  Exp Clin Psychopharmacol       Date:  2005-08       Impact factor: 3.157

5.  Transitions in patterns of heroin administration: a study of heroin chasers and heroin injectors.

Authors:  P Griffiths; M Gossop; B Powis; J Strang
Journal:  Addiction       Date:  1994-03       Impact factor: 6.526

6.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users.

Authors:  Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

Review 7.  Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users.

Authors:  Nicholas Meader; Ryan Li; Don C Des Jarlais; Stephen Pilling
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

8.  Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National AIDS Research Consortium.

Authors:  S R Friedman; B Jose; S Deren; D C Des Jarlais; A Neaigus
Journal:  Am J Epidemiol       Date:  1995-10-15       Impact factor: 4.897

9.  Hepatitis C virus infection among noninjecting drug users in New York City.

Authors:  Beryl A Koblin; Stephanie H Factor; Yingfeng Wu; David Vlahov
Journal:  J Med Virol       Date:  2003-07       Impact factor: 2.327

10.  Problematic use of prescription-type opioids prior to heroin use among young heroin injectors.

Authors:  Robin A Pollini; Caleb J Banta-Green; Jazmine Cuevas-Mota; Mitcheal Metzner; Eyasu Teshale; Richard S Garfein
Journal:  Subst Abuse Rehabil       Date:  2011-10
View more
  9 in total

1.  Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City.

Authors:  Kelly Quinn; Chunki Fong; Honoria Guarino; Pedro Mateu-Gelabert
Journal:  Drug Alcohol Depend       Date:  2018-11-28       Impact factor: 4.492

2.  Factors Influencing Uptake of Rapid HIV and Hepatitis C Screening Among Drug Misusing Adult Emergency Department Patients: Implications for Future HIV/HCV Screening Interventions.

Authors:  Roland C Merchant; Allison K DeLong; Tao Liu; Janette R Baird
Journal:  AIDS Behav       Date:  2015-11

3.  Brief intervention to increase emergency department uptake of combined rapid human immunodeficiency virus and hepatitis C screening among a drug misusing population.

Authors:  Roland C Merchant; Janette R Baird; Tao Liu; Lynn E Taylor; Brian T Montague; Ted D Nirenberg
Journal:  Acad Emerg Med       Date:  2014-07       Impact factor: 3.451

4.  Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals.

Authors:  Allison Mah; Mark W Hull; Kora DeBeck; Michael John Milloy; Sabina Dobrer; Ekaterina Nosova; Evan Wood; Thomas Kerr; Kanna Hayashi
Journal:  Int J Drug Policy       Date:  2017-03-24

Review 5.  Novel interventions to prevent HIV and HCV among persons who inject drugs.

Authors:  Phillip O Coffin; Christopher Rowe; Glenn-Milo Santos
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

6.  Methamphetamine administration dose effects on sexual desire, sexual decision making, and delay discounting.

Authors:  Meredith S Berry; Natalie R Bruner; Evan S Herrmann; Patrick S Johnson; Matthew W Johnson
Journal:  Exp Clin Psychopharmacol       Date:  2020-09-28       Impact factor: 3.157

7.  Innovations in education: A prospective study of storytelling narratives to enhance hepatitis C virus knowledge among substance users.

Authors:  Andrew H Talal; Yu-Xin Ding; Marianthi Markatou
Journal:  World J Hepatol       Date:  2022-05-27

8.  Within-subject evaluation of interim buprenorphine treatment during waitlist delays.

Authors:  Tatum N Oleskowicz; Taylor A Ochalek; Kelly R Peck; Gary J Badger; Stacey C Sigmon
Journal:  Drug Alcohol Depend       Date:  2021-01-20       Impact factor: 4.492

9.  Prescription opioid use, illicit drug use, and sexually transmitted infections among participants from a community engagement program in North Central Florida.

Authors:  Abenaa B Acheampong; Catherine W Striley; Linda B Cottler
Journal:  J Subst Use       Date:  2016-05-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.